ArticleScientific reports2026
Functional effects of EpCAM N-glycosylation in MDA-MB-468 breast cancer cells.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
EpCAM, the epithelial cell adhesion molecule, is a cancer cell marker whose expression is associated with worse prognosis in several epithelial cancers, including breast cancer. Despite being an attractive therapeutic target, it is unclear whether EpCAM plays a causative role in cancer progression and metastasis, and the mechanisms of this possible role remain unknown. To investigate EpCAM, we generated stable human MDA-MB-468 breast cancer cell lines with EpCAM knockout, EpCAM overexpression, or mutant unglycosylated EpCAM expression, in which all three normally N-glycosylated asparagine residues had been mutated to glutamines to abrogate EpCAM N-glycosylation. Our data establish that the lack of N-glycosylation in mutant unglycosylated EpCAM decreased EpCAM protein stability. EpCAM colocalization with cell membrane markers decreased in unglycosylated EpCAM, and colocalization with endoplasmic reticulum (ER) markers increased. Despite these clear effects on EpCAM protein stability and its subcellular localization, we did not observe any effects of unglycosylated EpCAM on the expression of downstream EpCAM targets including EGFR, E-cadherin, β-catenin, cyclin E, cyclin A, and c-myc. Similarly, there was no effect of unglycosylated EpCAM on cell viability, migration, invasion, or homotypic adhesion, although we did observe slight increases in homotypic cell-cell adhesion in EpCAM overexpressing cells. These findings show that N-glycosylation has a significant impact on stability and subcellular localization of EpCAM, but not on several critical breast cancer cell properties important for cancer progression and metastasis in human triple-negative MDA-MB-468 breast cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.